Introduction
Thalassemia, is the commonest genetic disorder in the world and represent a major health burden worldwide. It is a heterogeneous disorder that is recessively inherited and results from various mutations of the genes which code for globin chains of hemoglobin (Hb) leading to reduced or absent synthesis of globin chains.
[1] The reduced supply of globin diminishes the production of hemoglobin tetramers, causing hypochromia and microcytosis. Unbalanced accumulation of α and β subunits occurs because the synthesis of the unaffected globins proceeds at a normal rate. Unbalanced chain accumulation dominates the clinical phenotype. Clinical severity varies widely, depending on the degree to which the synthesis of the affected globin is impaired and the synthesis of other globin AYU | Jan-Mar 2014 | Vol 35 | Issue 1 trait is 3-18% in northern India and 1-3% or less in the south. A higher frequency is noted in certain communities, viz. Sindhis, Kutchis, Lohanas, Bhanushalis, Punjabis, Mahers, Agris, Goud Saraswats, Gowdas, etc.
[1] Also, 10,000 thalassemic children are born every year in India. [4] Nearly Rs. 1000 crore is spent for the treatment of thalassemia per annum. One out of every eight carriers of thalassemia worldwide lives in India. This is of particular importance in developing countries like India, where it increases the burden of health care delivery system. [5] The mainstay of managing these cases is repeated blood transfusion. Due to frequent blood transfusion, patients develops iron overload which results in growth failure, hypogonadism, diabetes, and hepatic disease. It can be reduced by regular chelation therapy. But iron chelators are costly and have side effects like growth retardation, visual and auditory toxicity, cataracts (with desferrioxamine) and arthropathy, and agranulocytosis (with deferiprone). [6] 
Aims and Objectives
To observe the efficacy of Triphaladi Avaleha as a hepato-splenoprotective agent, RBCs life prolonger and iron chelator in the management of thalassemia.
Materials and Methods

Selection of the patients
Pre-diagnosed patients of thalassemia major attending the OPD of Department of Kaumarabhritya, I. P. G. T. and R. A., Jamnagar, and also, patients registered in the thalassemia ward of G. G. Hospital, Jamnagar, fulfilling the criteria of selection, were enrolled in the study irrespective of age, sex, caste, etc.
Ethical clarence
The Institutional Ethics Committee gave clearance and approval for the clinical research protocol (PGT/T/Ethics/2009-2010/2157, dated 24/09/2009). Written consent of the parents of each patient was taken before starting the treatment. Basic information of the disease and treatment was given to the patients.
Criteria for selection of patients 1. Pre-diagnosed patients of thalassemia (diagnosed by the pediatrician of G. G. Hospital, Jamnagar 
Grouping and posology
Selected patients were randomly divided into two groups by simple random method. Patients of Group A were treated with Triphaladi Avaleha and modern medical management-Blood Transfusion (BT); while Group B treated with Modern medical management-BT and iron chelator (deferiprone). The dose of Avaleha for a child is not clearly mentioned in the classics. So, the dose was calculated according to Young's formula [7] keeping in mind the adult dose of Avaleha as 1 Pala (48 g) [8] with lukewarm milk (50-100 ml) as Anupana for 12 weeks duration.
Young's formula: (age/age + 12) × adult dose • 1-5 years age group: 4-14 g in three divided doses • 6-10 years age group: 16-22 g in three divided doses • 11-15 years age group: 23-27 g in three divided doses.
In Group B, the iron chelator (Tab. Deferiprone) was administered in dose of 75 mg/kg/day for 12 weeks duration. Follow up taken after 8 weeks in both the groups.
Assessment criteria
A special proforma was prepared to assess the clinical parameters (subjective and objective) with the scores, and to study the etiopathogenesis and response to the given treatment and any complications. The effect of therapy was assessed by counting the scores before and after 12 weeks of treatment.
Subjective parameters
Panduta (pallor), Hritdravatva (palpitation), Daurbalya (weakness), Balakshaya (chronic fatigue), Akshikootashotha (puffiness around the orbit), Jwara (irregular fever), Aruchi (anorexia), Udarashoola (abdominal pain), Pleehavriddhi (splenomegaly), Yakritvriddhi (hepatomegaly), Atisara (loose motion), Pindikodweshtana (leg cramps) and Sandhishoola (arthralgia).
Objective parameters
Routine hematological investigations (Hb%, TLC, DLC, ESR, PCV, MCV, MCH, and MCHC) and biological investigations [s. alb, s. glob, SGOT, SGPT, S. Alk. Phosphatase, S. Bil., S. Iron, Serum Total Iron Binding Capacity (S. TIBC), and S. Ferritin] were done in all patients twice, i.e., before and after the treatment schedule. Blood samples for hematological investigations were taken before BT.
Scoring pattern
The assessment was done based on the improvement in signs and symptoms, following a standard scoring pattern. [9] 
Dietary advice
Patients were advised to take low iron diet as well as to follow the restrictions regarding food habits and lifestyle, and to avoid the possible aggravating factors of thalassemia. 
Assessment of total effect of therapy
Statistical analysis
Student's "t" test (paired and unpaired) was applied for assessment of the result.
Selection of trial drug and preparation
The drugs were selected for the present study from Lohashodhana and Lohamarana Gana, [10] drugs used in Lohasevanajanya Vikara, [11] Yakrit and Pleehaa Vikara. [12] First of all, Yavakuta of all the 11 constituents (each 1200 g) of Triphaladi Avaleha was prepared. This was boiled with 16 times of water under low heat and reduced to one-eighth and filtered. Eighteen kilograms of Sharkara (sugar) was added to the decoction and again boiled till Avaleha is not formed. At this stage, fine powders of Prakshepa Dravya (adjuvant) was added. At the end, six kilograms Madhu was added after cooling of the Avaleha [ Table 1 ].
Observations
Totally 32 patients were enrolled in the present study, with 16 patients in each group. Of these patients, 24 completed the course of treatment (13 
Results
Effect of therapies
The trial drug showed highly significant results (P < 0.001) in the features of Panduta, Daurbalya, Akshikootashotha, and Jwara. Triphaladi Avaleha also gave significant results (P < 0.01) in the features of Udarashoola and Pleehavriddhi and significant results (P < 0.05) in Yakritvriddhi, Pindikodweshtana, and Sandhishoola [ Table 2 ]. The results with the control drug were insignificant (P > 0.1) in all the cardinal features except Yakritvriddhi which was significant (P < 0.05) [ Table 3 ].
In the patients treated with the trial drug, SGOT was decreased which was statistically significant (P < 0.01) and SGPT was also decreased which was significant (P < 0.05). The effect of the trial drug on all other parameters except SGOT and SGPT were found to be statistically insignificant (P > 0.1) [ Table 4 ], while the effect of the control drug on all the laboratory parameters was statistically insignificant (P > 0.1) [ Table 5 ].
Triphaladi Avaleha gave significant results (P < 0.01) in relieving Panduta and Sandhishoola and significant results (P < 0.05) in relieving Akshikootashotha, Jwara, and Pindikodweshtana in comparison to the control drug [ Table 6 ].
The trial group reduced serum ferritin level to 3.75%, while it was found increased by 23.96% in control group [ Table 7 ].
Post-treatment follow-up was done after 8 weeks of stopping the active treatment. Increase in BT, weight gain, height gain, splenomegaly, hepatomegaly, and clinical signs and symptoms were checked in the follow-up session. Triphaladi Avaleha increased the interval between BTs by 5 days in eight patients (61.53%) in the treated group. The control drug did not increase the interval between BTs in any patient in the control group. It was observed that 11 patients (84.62%) had a weight gain of 2 kg in the treated group while 4 patients (36.36%) had a weight gain of 1 kg in the control group. Ten patients (76.92%) had a height gain of 2 cm in the treated group, while there was no height gain in any of the patients of the control group. In the treated group, there was no further splenomegaly or hepatomegaly in any patient, while six patients (54.55%) in the control group had further splenomegaly of 1 cm. No further increase in the severity of signs and symptoms was observed in the treated group. No adverse effects were reported by any of the patients.
Overall effect of therapies
In trial group, five patients (38.46%) showed maximum improvement, five patients (38.46%) showed moderate improvement, two patients (15.38%) had mild improvement, while no improvement was seen in one patient (7.7%). In control group, two patients (18.18%) showed moderate improvement, four patients (36.36%) had mild improvement and five patients (45.46%) had no improvement [ Table 8 ].
Discussion
Hemoglobinopathies constitute a major public health problem internationally, particularly in the developing world as it has [13] Kakamachi, [14] Haridra, [15, 16] Guduchi, [17] Shweta Punarnava, and Sharapunkha [18] act in the Moola Sthanas of Rasavaha and Raktavaha Srotas. They have Pandughna, Bhedana, Pittasaraka, Yakrit-Pleehavriddhihara, Raktashodhana, Raktasthapana, and Shonitaprasadana properties which relieve Panduta, Akshikootashotha, Yakritvriddhi, and Pleehavriddhi. They are also hepatoprotective, which may help to decrease SGPT, SGOT, alkaline phosphatase, and s. bil. Drugs were selected from Lohashodhana and Lohamarana Gana, which may decrease serum iron and serum ferritin levels. Rasayana and Vayasthapana, as well as antioxidant and immunomodulatory activities enhance Bala and Vyadhikshamatva.
In short, Aamapachana, Deepana, Rochana, Jwaraghna, Vishaghna, Balavarnakara, Brimhana, Rasayana, and Tridoshahara properties do Vatapittashamana and relieve the signs and symptoms of thalassemia. Iron chelation may be done through Lohashodhana, Lohamarana, Lekhana, and Bhedana Karmas. Also, Raktashodhana, Raktaprasadana, Shonitasthapana, and Varnya properties decrease the rapid destruction of RBCs, thus prolonging their life span, which increases the interval of BT. All these factors improve the quality of life of thalassemic patients.
Serum ferritin level is the hematological criterion for assessing iron overload in thalassemic patients. Decreased serum ferritin indicates decreased iron overload in the patients. Though the comparative data are statistically not significant, the trial group decreased serum ferritin level by 3.75%, while in control group, serum ferritin level was increased by 23.96%. This showed that trial drug had good result to decrease the iron overload in thalassemic patients in comparison to control drug. The level of serum iron was increased. No particular reason was found for the decrease in serum ferritin and increase in serum iron levels. Further extensive studies are needed to evaluate these findings.
Conclusion
There is no exact correlation for thalassemia in Ayurveda. Beejabhagavayavadushti is found to be the chief factor in this disease. Prevention can be achieved through Atulyagotriya Vivaha as well as modern diagnostic techniques. Triphaladi Avaleha has various properties which help to relieve the signs and symptoms of the disease, as well as decrease the iron overload. So, it can be given as an adjuvant therapy with modern medical management.
